Biomarkers for assessment of intestinal permeability in clinical practice
Autor: | Jens Walter, Julie-Anne Nazare, Audrey M. Neyrinck, Stephan C. Bischoff, Nathalie M. Delzenne, B. Seethaler, M Basrai |
---|---|
Přispěvatelé: | University of Hohenheim, Université Catholique de Louvain = Catholic University of Louvain (UCL), Louvain Drug Research Institute [Bruxelles, Belgique] (LDRI), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), University of Alberta, University College Cork (UCC), CarMeN, laboratoire |
Rok vydání: | 2021 |
Předmět: |
Adult
Male medicine.medical_specialty Physiology [SDV]Life Sciences [q-bio] Overweight Fatty Acid-Binding Proteins Gastroenterology Permeability 03 medical and health sciences 0302 clinical medicine Physiology (medical) Internal medicine Lbp zonulin Medicine Humans Obesity Prospective Studies Intestinal Mucosa Protein Precursors Prospective cohort study 030304 developmental biology 2. Zero hunger 0303 health sciences Intestinal permeability Hepatology gut barrier Haptoglobins business.industry Zonulin medicine.disease gut health Gastrointestinal Microbiome [SDV] Life Sciences [q-bio] Cross-Sectional Studies Cohort Biomarker (medicine) 030211 gastroenterology & hepatology gut permeability Female Calprotectin medicine.symptom business Body mass index Biomarkers |
Zdroj: | AJP-Gastrointestinal and Liver Physiology AJP-Gastrointestinal and Liver Physiology, American Physiological Society, 2021, 321 (1), pp.G11-G17. ⟨10.1152/ajpgi.00113.2021⟩ AJP-Gastrointestinal and Liver Physiology, 2021, 321 (1), pp.G11-G17. ⟨10.1152/ajpgi.00113.2021⟩ |
ISSN: | 1522-1547 0193-1857 |
Popis: | International audience; Intestinal permeability is an important diagnostic marker, yet its determination by established tests, which measure the urinary excretion of orally administered tracer molecules, is time consuming and can only be performed prospectively. Here, we aim to validate proposed surrogate biomarkers, which allow measuring intestinal permeability more easily. In this cross-sectional study, we included two independent cohorts comprising nonobese (Healthy cohort, n = 51) and individuals with obesity (Obesity cohort, n = 27). The lactulose/mannitol (lac/man) ratio was determined in all individuals as an established marker of intestinal permeability. Furthermore, we measured six potential surrogate biomarkers, being albumin, calprotectin, and zonulin, measured in feces, as well as intestinal fatty acid binding protein (I-FABP), lipopolysaccharide binding protein (LBP) and zonulin, measured in plasma. Correlation analyses and multiple linear regression models were conducted to assess possible associations between the established lac/man ratio and the proposed biomarkers by also evaluating a potential effect of age, body mass index (BMI), and sex. The lac/man ratio correlated with plasma LBP levels in all cohorts consistently and with the amount of fecal zonulin in overweight and obese individuals. Multiple linear regression models showed that the association between the lac/man ratio and plasma LBP was independent of age, BMI, and sex. Fecal zonulin levels were associated with the lac/man ratio as well as BMI, but not age and sex. Our data suggest plasma LBP as a promising biomarker for intestinal permeability in adults and fecal zonulin as a potential biomarker in overweight and obese individuals.NEW & NOTEWORTHY This study shows that biomarkers from blood and fecal samples are associated with the cumbersome established tests of intestinal permeability throughout different cohorts. Therefore, such biomarkers could be used to assess gut barrier function in prospective cohort studies and large-scale clinical trials for which tracer-based tests may not be feasible. |
Databáze: | OpenAIRE |
Externí odkaz: |